Osiris Therapeutics, Inc. Product Pipeline Review 2012: ResearchMoz

ResearchMoz.us include new market research report "Osiris Therapeutics, Inc. Product Pipeline Review 2012 " to its huge collection of research reports. Osiris Therapeutics, Inc. - Product Pipeline Review - 2012 provides data on the Osiris Therapeutics, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.  This report is built using data and information sourced from Global Markets Directs proprietary databases, Osiris Therapeutics, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Osiris Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope
- Osiris Therapeutics, Inc. - Brief Osiris Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Osiris Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Osiris Therapeutics, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
- Recent updates of the Osiris Therapeutics, Inc.s pipeline in the last quarter. 
- Key discontinued and dormant projects. 
- Latest news and deals relating to the products.

Reasons to buy
- Evaluate Osiris Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline. 
- Assess the growth potential of Osiris Therapeutics, Inc. in its therapy areas of focus. 
- Identify new drug targets and therapeutic classes in the Osiris Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
- Exploit collaboration and partnership opportunities with Osiris Therapeutics, Inc.. 
- Avoid Intellectual Property Rights related issues. 
- Explore the dormant and discontinued projects of Osiris Therapeutics, Inc. and identify potential opportunities in those areas.

For More Information, Please Visit@ Osiris Therapeutics

Table Of Contents

List of Tables 4
List of Figures 4
Osiris Therapeutics, Inc. Snapshot 5
Osiris Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Osiris Therapeutics, Inc. Research and Development Overview 6
Key Therapeutic Areas 6
Osiris Therapeutics, Inc. Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products Monotherapy 9
Osiris Therapeutics, Inc. Pipeline Products Glance 10
Osiris Therapeutics, Inc. Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Osiris Therapeutics, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Osiris Therapeutics, Inc. Drug Profiles 13
Chondrogen 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Osteocel-XC 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
remestemcel-L 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Osiris Therapeutics, Inc. Pipeline Analysis 17
Osiris Therapeutics, Inc. Pipeline Products by Therapeutic Class 17
Osiris Therapeutics, Inc. Pipeline Products by Route of Administration 18
Osiris Therapeutics, Inc. Recent Pipeline Updates 19
Osiris Therapeutics, Inc. - Dormant Projects 21
Osiris Therapeutics, Inc. Company Statement 22
Osiris Therapeutics, Inc. Locations And Subsidiaries 23
Head Office 23
Osiris Therapeutics, Inc., Recent Developments 24
Osiris Therapeutics, Inc.- Press Release 24
Sep 28, 2012: Osiris Therapeutics Regains Worldwide Rights To Chondrogen 24
Sep 28, 2012: Osiris Therapeutics Regains Worldwide Rights To Prochymal 24
Sep 28, 2012: Osiris Therapeutics's Prochymal To Be Evaluated Under Swissmedic's Rapid Authorization Procedures 24
Jul 02, 2012: Osiris Therapeutics's Prochymal Significantly Reduces Hypertrophy, Arrhythmia And Progression To Heart Failure In Patients Suffering Heart Attack 25

View Full Report@ http://www.researchmoz.us/osiris-therapeutics-inc-product-pipeline-review-2012-report.html

Jun 29, 2012: Osiris Annouces Expansion Of Intellectual Property Protection Covering Prochymal 26
Jun 14, 2012: Osiris Receives Second Approval for Life-Saving Stem Cell Drug Prochymal 27
May 17, 2012: Osiris Receives Marketing Clearance From Health Canada For Prochymal 28
Jan 03, 2012: Osiris Therapeutics Provides Update On Stem Cell Trial For Type 1 Diabetes 29
Dec 02, 2009: Osiris Reports Positive Two-Year Data On Stem Cell Treatment For Acute Myocardial Infarction 30
Sep 08, 2009: Osiris Therapeutics Announces Preliminary Results For Prochymal Phase III GvHD Trials 30
Sep 08, 2009: Osiris' Stem Cell Drug Fails In Two Late-Stage Trials 31
Jul 28, 2009: Osiris Achieves Milestone Payment For Progress Developing Stem Cell Therapy For Prochymal 32
Jun 23, 2009: Osiris Therapeutics Reports Interim Data For COPD Stem Cell Study 32
Apr 17, 2009: Osiris Completes Enrollment In Second Prochymal Phase III Trial For Graft vs. Host Disease 33
Apr 02, 2009: Osiris Treates First Patient In Phase II Stem Cell Trial For Heart Attacks 34
Mar 27, 2009: Osiris Discontinues Enrollment In Crohn's Study Due To Concerns With Trial Design 35
Jan 15, 2009: Osiris and FDA Reach Agreement On Submission Of First Marketing Application For A Stem Cell Product 35
Financial Deals Landscape 37
Osiris Therapeutics, Inc., Deals Summary 37
Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 38
Partnerships 38
Genzyme Enters Into Agreement With Osiris Therapeutics 38
Osiris Therapeutics Enters Into An Agreement With Juvenile Diabetes Research Foundation International 40
Osiris Therapeutics Enters Into An Agreement With Genzyme 41
Equity Offering 43
Osiris Therapeutics Completes Private Placement Of $12 Million 43
Osiris Therapeutics Completes Private Placement Of $20 Million 45
Osiris Completes IPO Of $38.5 Million 47
Debt Offering 49
Osiris Therapeutics Completes Private Placement Of Convertible Debt For $20 Million 49
Asset Transactions 50
NuVasive Acquires Osteocel Business From Osiris Therapeutics 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

To know more about this reports, please visit @ http://www.researchmoz.us/osiris-therapeutics-inc-product-pipeline-review-2012-report.html

See All Latest Market Research Report@ http://www.researchmoz.us/report.html

Contact: sales@researchmoz.us for further information. 

Find us on: